

CENTERS FOR DISEASE CONTROL AND PREVENTION (**Final 6-27-05**)
 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
 MARRIOTT CENTURY CENTER HOTEL
 ATLANTA, GEORGIA
 JUNE 29-30, 2005

<u>AGENDA ITEM</u>	<u>PURPOSE/ACTION</u>	<u>PRESIDER/PRESENTER(S)</u>
June 29		
8:00 Welcome		Dr. M. Levin (Chair, ACIP) Dr. L. Pickering (CDC, OD)
8:30 <u>Tdap Adolescent Recommendation</u>		
Pertussis Working Group Update	Information	Dr. J. Abramson (ACIP)
Adolescent Pertussis and Tdap	Information	Dr. M. Cortese (NIP)
Tetanus and diphtheria containing vaccines	Information	Dr. T. Murphy (NIP)
Safety monitoring	Information	Dr. J. Iskander (OD)
Supply, planned studies	Information	TBD (GSK, Sanofi Pasteur)
Use of Tdap among adolescents 11-18 years	Decision VFC Vote	Dr. K. Broder (NIP) Dr. G. Wallace (NIP)
10:30 BREAK		
11:00 Hepatitis B Vaccine Recommendation	Information	Dr. E. Mast (NCID)
Childhood recommendations	Discussion Decision	
12:30 LUNCH		
1:30 Recommendations for Use of Hepatitis A	Information Discussion	Dr. B. Bell (NCID) Dr. G. Armstrong (NCID)
2:30 MMRV Working Group/Introduction	Information	Dr. J. Campbell (ACIP)
Overview of Varicella Epidemiology		Dr. D. Guris (NIP)
Physician survey results		Dr. Marin (NIP)
3:30 BREAK		
4:00 Update cost-effectiveness analysis		Dr. F. Zhou (NIP)
Summary of AAP recommendations		Dr. C. Meissner (Tufts)
<u>Votes</u>		
Routine 2 nd dose vaccination at 4-6 yrs of age	Discussion & Vote	Dr. J. Seward (NIP)
Catch-up vaccination with 2 nd dose of children 7-12 yrs of age who have only rec'd 1 dose	Discussion & Vote	
School-entry requirements for middle and high schools and colleges	Discussion & Vote	
Vaccination of susceptible persons \geq years of age	Discussion & Vote	
Routine screening of pregnant women & post- partum vaccination of susceptible women	Discussion & Vote	
Expanding recommendation on vaccination of HIV (+) children	Discussion & Vote	

Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP.

	Second dose varicella	*Discussion & Vote (VFC)	Dr. G. Wallace (NIP)
5:30	General Recommendations Work Group : Vaccine storage and handling	Information	Dr. A. Kroger (NIP)
6:15	Revised Adult Immunization Schedule	Information Decision	Dr. R. Strikas (NIP)
6:30	Public Comment		
6:45	ADJOURN		

<u>AGENDA ITEM</u>	<u>PURPOSE/ACTION</u>	<u>PRESIDER/PRESENTER(S)</u>	
June 30			
8:00	Unfinished Business		
8:30	Disease burden and epidemiology zoster vaccine trial results	Information	TBD
	Zoster vaccine clinical trial results	Information Discussion	Dr. P. Annunziato (Merck)
9:15	<u>Tdap – Use in Adults</u> Epidemiology of pertussis in adults Potential strategies using Tdap – Overview	Information Discussion	Dr. K. Kretsinger (NIP) Dr. T. Murphy (NIP)
10:15 BREAK			
10:45	Human Papilloma Virus Workgroup Overview HPV natural history Cervical cancer epidemiology, Pap screening and burden of disease HPV vaccine cost-effectiveness	Information	Dr. L. Markowitz (NCHSTP) Dr. B. Unger (NCID) Dr. H. Lawson (NCCDPHP) Dr. S. Goldie (Harvard)
12:30 LUNCH			
1:30	ACIP/NVAC Joint Working Group: Preliminary results on pandemic vaccine prioritization	Information Discussion	Dr. C. Bridges (NIP)
2:15	ACIP/HICPAC joint statement on immunization of health care workers against influenza	Discussion Decision	Dr. M. Pearson (HICPAC/NCID)
2:30	The effectiveness of an investigational pentavalent (Human-Bovine) reassortant rotavirus vaccine (PRV) to reduce health care utilization for rotavirus gastroenteritis	Information	Dr. P. Heaton (Merck)
	Issues concerning the rotateq vaccine	Information	Dr. U. Parashar (NIP)

Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP.

3:00	HIV Vaccine Working Group Update	Information Discussion	Dr. G. Birkhead (ACIP)
3:10	Updates: Ex-officios and CDC		
3:20	Public Comment		
3:35	ADJOURN		

Note: * These votes will be taken only if appropriate in light of prior decisions by or ACIP.